Abaxis (ABAX) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Abaxis Reports Financial Performance for the Second Quarter of Fiscal 2016
October 27, 2015 4:01 PM EDTUNION CITY, Calif., Oct. 27, 2015 /PRNewswire/ --Â Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, today reported financial results for the second fiscal quarter ended September 30, 2015.
Second quarter overview:
Revenues from continuing operations of $56.0 million, up 11% over last year's comparable quarter. Diluted EPS from continuing operations of $0.34, up 36% over last year's comparable quarter. Diluted EPS, including discontinued operations, of $0.34, up 42% over last year's comparable quarter.Revenues highlights:
North... More